You need to sign in or sign up before continuing.


  • Trials · Sep 2018

    Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial.

    • Jian-Guo Zhou, Nan-Jing Zhou, Qiong Zhang, Yao-Yao Feng, and Hang Zhou.
    • Department of Oncology, Affiliated Hospital of Zunyi Medical University, NO.149, Dalian Road, Zunyi, 563000, China. jianguo.zhou@yahoo.com.
    • Trials. 2018 Sep 17; 19 (1): 500.

    BackgroundIn China, cervical cancer is the fifth most commonly diagnosed cancer, and the outcomes for patients with advanced or recurrent disease are poor. Apatinib, a small molecule inhibitor of vascular endothelial growth factor receptor (VEGFR-2), is an orally bioavailable agent, which has shown survival benefit in multiple solid tumors. Based on previous research, this phase II clinical trial aims to verify apatinib's efficacy and safety in patients with advanced or recurrent cervical cancer.Methods/DesignThis randomized, parallel arm, open-label, interventional trial will be carried out to evaluate the efficacy and the safety of apatinib for advanced or recurrent cervical cancer. A total of 60 eligible patients will be allocated by intention, in a ratio of 1:1, to either the experimental group or the control group. The primary endpoint is progression-free survival, the secondary endpoints include overall survival, disease control rate, objective response rate, quality of life, and adverse events. Assessments will be carried out before enrolment (baseline) and every 4 weeks after treatment.DiscussionThe aim of this trial is to demonstrate the clinical effect, safety, and side effects of apatinib in the treatment of advanced or recurrent cervical cancer. This study will clarify the efficacy and safety of this regimen.Trial RegistrationChinese Clinical Trials Registry, ChiCTR-OIN-17012164 . Registered on 24 July 2017.

      Pubmed     Free full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.